Background In times of financial hardship, making innovative treatments affordable for society, accessible for patients and profitable for pharmaceutical companies is a challenge. Reimbursement is often threatened by uncertainties about the financial impact or evidence for a treatment. A contractual agreement between the payer and pharmaceutical company can link reimbursement to financial thres...

This study utilizes panel regression model to explore the relationships between corporate performance and the patent performance measured from patent H index, current impact index (CII), and essential patent index (EPI) in the pharmaceutical company. The results demonstrate that patent H index and EPI have positive influences upon corporate performance. Furthermore, this study developed a class...

Dept. of Neurology, Clinical research group for Multiple Sclerosis, University of Würzburg, Würzburg, Germany Dept. of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands Dept. Infectious Diseases and Immunology, Div. Immunology, Faculty of Veterinary Medicine, Utrecht University, The Netherlands Members of UNYPHAR, a network collaboration between t...

The rise of biotechnology in the 1970s ushered in a change in innovation strategies in the pharmaceutical industry. The vertically-integrated company become more reliant on a distributed innovation structure in which large corporations integrate the knowledge generated by a network of actors, including small biotechnology firms and public research organisations. In this context, it is important...

archive of alcohol lireratu publishing modern abstract bulletins company pharmaceutical abstract bulletin a punched card abstract file on solid state and tra the abstract of the technical report relation of an abstract to its original from journal article to abstract

The Act on the Reform of the Market for Medicinal Products (“AMNOG”) introduced an early benefit assessment (EBA) of pharmaceuticals in Germany in 2011. According to this law, all pharmaceuticals with a new active agent made available on the market for the first time have to go through a benefit assessment process. A benefit assessment dossier has to be submitted at the time of the market entry...

Aurigene Discovery Technologies, the Bangalore-based biotech company, and Pierre Fabre, the second largest independent French pharmaceutical company, announced on February 11, 2014, a collaborative license, development and commercialization agreement giving Pierre Fabre worldwide rights (excluding India) to a new immune checkpoint modulator, AUNP-12, for the treatment of cancer. Aurigene will r...

BACKGROUND Medical students are targeted by the pharmaceutical industry and are exposed to their marketing strategies even in the preclinical years of study. The marketing strategies used by pharmaceutical companies with physicians are also applied to students, affecting their future prescribing behaviour, and include low-cost non-educational gifts, travel expenses and conferences registration ...

In a cost conscious society the research based pharmaceutical company is increasingly being portrayed as a profiteer and the company manufacturing generic drugs as a cutter of costs to the NHS. Clearly such an extreme view is both shortsighted and wrong, particularly as unreasonable profits are prevented by the direct control of the Department of Health. In putting the case for prescribing drug...